Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal C oligosaccharide conjugated vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal C oligosaccharide conjugated vaccines are active immunizing agents designed to prevent invasive disease caused by *Neisseria meningitidis* serogroup C. These vaccines contain purified capsular polysaccharides from the bacteria, which are chemically linked (conjugated) to a carrier protein such as CRM197 or tetanus toxoid. This conjugation enhances the immune response, especially in young children who respond poorly to plain polysaccharides. The primary mechanism of action is induction of protective antibodies against the capsular polysaccharides of *Neisseria meningitidis* serogroup C. Some formulations also protect against additional serogroups (A, W-135, Y). The main indication is prevention of invasive meningococcal disease including meningitis and septicemia[4][5][7][8]. Major developers include GSK and Pfizer.
- Brand names
- MenveoMenactra
- Other names
- meningococcal (groups A, C, W-135 and Y) oligosaccharide CRM197 conjugate vaccinemeningococcal polysaccharide diphtheria conjugate vaccinemeningococcal C conjugate (Men-C) vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal C oligosaccharide conjugated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal C oligosaccharide conjugated vaccine.